Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

被引:9
|
作者
van Trier, Tinka J. [1 ]
Snaterse, Marjolein [1 ]
Hageman, Steven H. J. [2 ]
ter Hoeve, Nienke [3 ,4 ]
Sunamura, Madoka [3 ,5 ]
Moll van Charante, Eric P. [6 ]
Galenkamp, Henrike [7 ]
Deckers, Jaap W. [8 ]
Martens, Fabrice M. A. C. [9 ]
Visseren, Frank L. J. [2 ]
Scholte Op Reimer, Wilma J. M. [1 ,10 ]
Peters, Ron J. G. [1 ]
Jorstad, Harald T. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Cardiol, Amsterdam Cardiovasc Sci, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Med Ctr Utrecht, Dept Vasc Med, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[3] Capri Cardiac Rehabil Rotterdam, Max Euwelaan 55, NL-3062 MA Rotterdam, Netherlands
[4] Erasmus MC, Dept Rehabil Med, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[5] St Franciscus Gasthuis, Dept Cardiol, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands
[6] Amsterdam Univ Med Ctr, Dept Gen Practice, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[7] Amsterdam Univ Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Publ & Occupat Hlth, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[8] Erasmus MC, Dept Cardiol, Thoraxctr, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[9] Deventer Hosp, Dept Cardiol, N Bolkesteinlaan 75, NL-7416 SE Deventer, Netherlands
[10] HU Univ Appl Sci Utrecht, Res Grp Chron Dis, Padualaan 99, NL-3584 CH Utrecht, Netherlands
关键词
Risk stratification; Lifetime risk; Cardiovascular risk factors; Secondary prevention; Residual risk; MYOCARDIAL-INFARCTION; WAIST CIRCUMFERENCE; EUROPEAN GUIDELINES; PREVENTION PROGRAM; CLINICAL-PRACTICE; LIFE-STYLE; CARDIOLOGY; COUNTRIES; THERAPY; SOCIETY;
D O I
10.1093/eurjpc/zwad038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control. Aims This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event. Methods and results Pooled data from six studies are as follows: RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged >= 45 years at >= 6 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0-1.8) after index event, 10-year risk was median (IQR) 20% (15-27%) and lifetime risk 54% (47-63%). Whereas 70% used conventional medication, 82% had >= 1 drug-modifiable risk factor not on target. Furthermore, 91% had >= 1 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4-8%) and of lifetime risk to 20% (15-27%) and a median (IQR) gain of 7.3 (5.4-10.4) atherosclerotic cardiovascular disease event-free years. Conclusions Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime. Lay Summary Patients with heart disease are at high risk of new cardiac events. This study amongst 3230 patients who had a heart attack or received a stent or bypass surgery shows missed potential for healthy life after a heart attack. The average age of study patients was 61 years, and 24% were women. At 1 year after the cardiac event, nearly one in three (30%) continued smoking, 79% were overweight, 45% reported insufficient physical activity, 40% had high blood pressure, and 65% had a too high LDL ('bad') cholesterol. We calculated that adherence to lifestyle advice and medications could on average halve the risk for another heart attack and add over 7 healthy years of life after a heart attack. This highlights the importance of healthy lifestyle and medication adherence after a heart attack. Key finding:center dot adherence to lifestyle advice and medications could add over 7 healthy years of life after a heart attack
引用
收藏
页码:601 / 610
页数:10
相关论文
共 50 条
  • [1] Periodontal disease, a risk factor for atherosclerotic cardiovascular disease
    Gheorghita Dorottya
    Eordegh Gabriella
    Nagy Ferenc
    Antal Mark
    [J]. ORVOSI HETILAP, 2019, 160 (11) : 419 - 425
  • [2] Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
    Toshiyuki Nishikido
    [J]. Cardiovascular Diabetology, 22
  • [3] Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
    Nishikido, Toshiyuki
    [J]. CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [4] Potential Influence of Risk Factor Control on the Association Between Lipoprotein(a) and Atherosclerotic Cardiovascular Disease
    Ghouse, Jonas
    Ahlberg, Gustav
    Rand, Soren Albertsen
    Olesen, Morten Salling
    Vilhjalmsson, Bjarni
    Stender, Stefan
    Bundgaard, Henning
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2024, 44 (06) : 1455 - 1457
  • [5] Atherosclerotic Cardiovascular Disease Risk and Longitudinal Risk Factor Management Among Patients With Breast Cancer
    Melson, John W.
    Koethe, Benjamin
    Mohanty, Sharanya
    Babroudi, Seda
    Bao, Chen
    Chunduru, Amar
    Dwaah, Henry
    Finn, Matthew
    Jain, Annika
    Lalla, Mumtu
    Patnaik, Paras
    Studley, Rachael
    Buchsbaum, Rachel J.
    Huber, Kathryn
    Parsons, Susan K.
    Upshaw, Jenica N.
    [J]. CLINICAL BREAST CANCER, 2024, 24 (02) : e71 - e79.e4
  • [6] Choice of initial treatment with cholesterol lowering drugs in patients with familial hypercholesterolemia, atherosclerotic cardiovascular disease, or increased risk of atherosclerotic cardiovascular disease
    Hoe, Jakob Kronkvist
    Jensen, Camilla B.
    Hansen, Susanne
    Olsen, Rasmus Huan
    Johansen, Tina
    Jimenez-Solem, Espen
    Petersen, Janne
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 178 - 179
  • [7] ECONOMIC BURDEN OF DIABETIC PATIENTS WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Marcellusi, A.
    Sciattella, P.
    Bini, C.
    Rotundo, M.
    Aimaretti, G.
    Mennini, F. S.
    [J]. VALUE IN HEALTH, 2020, 23 : S509 - S509
  • [8] HOMOCYSTEINEMIA, AN INDEPENDENT, TREATABLE RISK FACTOR FOR ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE IN HYPERLIPIDEMIC PATIENTS
    GLUECK, CJ
    SHAW, P
    WANG, Y
    LANG, J
    TRACY, T
    SIEVESMITH, L
    [J]. CLINICAL RESEARCH, 1994, 42 (03): : A359 - A359
  • [9] Prevalence, awareness, treatment, and risk factor control of high atherosclerotic cardiovascular disease risk in Guangzhou, China
    Liu, Hui
    Lin, Weiquan
    Tu, Kexin
    Zhou, Qin
    Wang, Chang
    Sun, Minying
    Li, Yaohui
    Liu, Xiangyi
    Lin, Guozhen
    Li, Sidong
    Bao, Wei
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [10] Potential pathophysiologic mechanisms underlying the inherent risk of cancer in patients with atherosclerotic cardiovascular disease
    Di Fusco, Stefania Angela
    Cianfrocca, Cinzia
    Bisceglia, Irma
    Spinelli, Antonella
    Alonzo, Alessandro
    Mocini, Edoardo
    Gulizia, Michele Massimo
    Gabrielli, Domenico
    Oliva, Fabrizio
    Imperoli, Giuseppe
    Colivicchi, Furio
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 363 : 190 - 195